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Potential cardiovascular risk factors in chronic kidney disease:
AGEs, total homocysteine and metabolites, and the C-reactive
protein.
Background. Total homocysteine (tHcy) and advanced gly-
cation end-products (AGEs) are implicated in the patho-
genesis of vascular damage. This study aimed to investigate
whether elevated serum levels of the AGEs pentosidine, Ne-
carboxymethyllysine (CML) and imidazolone; tHcy, cystathio-
nine, methylmalonic acid (MMA), and 2-methylcitric acid
(2-MCA), as well as C-reactive protein (CRP), are related to a
higher risk for cardiovascular events.
Methods. A total of 232 patients with chronic kidney dis-
eases (mean age 57.6 ± 13.1 years, 82 female and 150 male);
99 with chronic renal failure (CRF), 84 maintenance hemodial-
ysis patients and 49 renal transplant recipients were followed
for 2 years. The relationship between the parameters of inter-
est, conventional risk factors and elevated levels of CRP with
cardiovascular events was tested in all subjects by the Cox pro-
portional hazards model.
Results. Mean serum levels of AGEs, tHcy, and of the metabo-
lites were found to be significantly increased in all three groups
compared to the healthy subjects (P < 0.01, respectively). Fifty-
three cardiovascular events occurred during follow-up; a total
of 40 patients died. Final multivariate analysis showed diabetes
(RR 2.06, 95% CI 1.17–3.60, P = 0.013), end-stage renal disease
(ESRD) (RR 4.88, 95% CI 2.40–9.89, P < 0.001) and elevated
CRP levels (RR 2.00, 95% CI 1.11–3.60, P = 0.021) as indepen-
dent risk factors for cardiovascular events.
Conclusion. Data from a group consisting of patients with
CRF, patients undergoing maintenance hemodialysis treat-
ment, and renal transplant recipients provide evidence that con-
ventional risk factors such as the presence of diabetes, ESRD,
as well as elevated levels of the considered risk factor CRP,
seem to play a more important role for cardiovascular outcome
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in patients with chronic kidney disease than elevated levels of
AGEs, tHcy, and related metabolites. The evidence suggests
that routine CRP measurement can be recommended in cases
of chronic renal insufficiency.
Atherosclerotic vascular complications are the major
cause of morbidity and mortality in patients with chronic
kidney disease of different stages. The multifactorial ori-
gin of the cause is not yet well understood [1, 2]. The
association between conventional risk factors, a chronic
uremic state together with malnutrition and chronic in-
flammation seems to be a major source of oxidant stress
[3, 4] playing a role in the pathogenesis of vascular
damage. Advanced glycation end-products (AGEs) are
involved by acting with receptors leading to the pro-
duction of free oxygen radicals followed by the release
of cytokines [5]. Based on the chemical pathway of
AGE formation, it is supposed that patients suffering
from diabetes mellitus are particularly prone to increased
risk due to AGE accumulation [5, 6]. AGEs have been
found to be colocalized in arterial and cardiac tissue
as well as in atherosclerotic lesions of uremic patients
[6, 7]. While the formation of the AGEs pentosidine and
Ne-carboxymethyllysine (CML) is closely related to ox-
idative stress–induced damage [8], imidazolone is a con-
densation product of proteins and the nonoxidatively
formed 3-deoxyglucosone [6], thus can be suitably used
as a marker of the nonoxidative pathway of AGE forma-
tion. The relationship between AGE-modified peptides
[9] and AGEs, which accumulate with deteriorating re-
nal function [10, 11], and cardiovascular complications, is
still in discussion. The influence of nutritional status and
conditions of chronic inflammation, as expressed by ele-
vated levels of C-reactive protein (CRP) found in chronic
renal failure (CRF) [4, 11–13], remains open. The same
is true for the significance of increased levels of total ho-
mocysteine (tHcy), which are suggested as being a new
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independent risk factor for atherosclerotic vascular dis-
ease [14], especially in patients with chronic renal failure
or end-stage renal disease (ESRD) [15–17]. Homocys-
teine acts as a prooxidant agent via the autoxidation of
free thiols leading to superoxide production [18] as well
as through molecular targeting [19]. Its increase in ure-
mia is additionally enhanced by vitamin malnutrition and
functional deficiencies of the vitamin B12, folic acid, and
vitamin B6 [15].
The aim of this prospective study was to investi-
gate whether increased levels of AGEs, tHcy and its
metabolites, and the CRP, are linked to a higher risk for
atherothrombotic events in patients with chronic renal
disease.
METHODS
Study population
A total of 232 patients with chronic kidney dis-
eases comprising 99 patients with CRF before starting
dialysis treatment (67 nondiabetics and 32 diabetics),
84 patients on maintenance hemodialysis treatment (53
nondiabetics and 31 diabetics) and 49 patients after
renal transplantation (42 nondiabetics and seven dia-
betics) were included in the study. The 70 diabetics
consisted of 67 type 2, three type 1 (two in hemodialysis
and one in CRF). Reference ranges of AGEs, tHcy, and
metabolites were calculated using the sera of 51 healthy
volunteers (30 women and 21 men, mean age 41.7 ±
14.4 years) as controls. All of them had normal renal func-
tion as reflected by creatinine Cockroft clearance within
the normal range. None was acutely ill or revealed clinical
signs of a chronic disease state, including atherothrom-
botic vascular changes of any type. The controls received
no vitamin supplementation for at least three months.
Material presented previously [20] was used in this study,
changes in the numbers of patients are due to lack of cer-
tain data. All patients who checked into our dialysis unit
or the outpatient department (including renal transplant
recipients) within the 4-week period of recruitment, and
who were expected to have the follow-up treatment in our
department, were asked to participate in the study. Each
participant provided written informed consent. By the
end of the recruitment period, the study group was rep-
resentative of the clinical population in our department;
representing 83% of our intermittent hemodialyzed pa-
tients (N = 101), nearly 50% of our CRF patients as well
as 15% of the renal transplant recipient patients routinely
seen in the outpatient department.
In this study, patients were classified as having
CRF when the serum creatinine level was higher than
150 lmol/L; the mean duration of CRF was 46.0 ±
54.6 months (median 35 months, ranging from 1 to
274 months). Dialysis treatment was performed three
times a week for 3.5 to 5 hours. Forty-nine patients were
dialyzed using low-flux cellulosic membranes and 35 pa-
tients with high-flux synthetic membranes (polycarbon-
ate or polyamide). The mean time on dialysis was 37 ±
30 months (median 29 months, ranging from 4 to
188 months). After each dialysis session, the patients
were treated with oral vitamin supplementation, consist-
ing of vitamin B6 10 mg, cobalamin 6 lg, folic acid 1 mg,
and biotin 0.3 mg. In the renal transplant recipients,
the mean time after transplantation at baseline was
36.4 ± 17 months (median 17 months, ranging from
1 to 172 months). None of the CRF or renal trans-
plant recipient patients received vitamin B6, vitamin B12,
or folic acid supplementation. Antihypertensive treat-
ment consisted mainly of angiotensin-converting enzyme
(ACE) inhibitors (92% in CRF, 81% in hemodialysis
patients, and 37% in renal transplant recipients), b re-
ceptor blockers (45%, 65%, and 40%, respectively), and
calcium antagonists (18%, 27%, and 85%, respectively).
Lipid-lowering drugs were used in 28% of CRF, 21% of
hemodialysis patients, and 37% of renal transplant re-
cipients. A dose of 100 mg/day aspirin was given in 17%
of CRF, 35% of hemodialysis patients, and 16% of renal
transplant recipients.
Renal diseases
Renal diseases in the different groups were clas-
sified for glomerulonephritis (26.3% in CRF/27.4%
in hemodialysis patients/55.1% in renal transplant
recipients), diabetic nephropathy (16.2%/31%/6.1%),
interstitial nephritis (22.2%/23.8%/4.1%), polycystic kid-
ney disease (3%/10.7%/8.2%), and hypertensive kid-
ney disease (2%/4.8%/2%) as well as other causes
(30.3%/7.1%/24.5%).
History of cardiovascular events/diabetes
mellitus/smoking behavior
The presence of cardiovascular disease at baseline
was defined if at least one of the following events oc-
curred before the time of entry (records of former hos-
pitalization and of outpatient clinics were used): acute
myocardial infarction due to clinical and ECG or labo-
ratory changes, angina pectoris based on clinical charac-
teristics, cerebrovascular diseases, including hemorrhagic
or occlusive stroke or transitoric ischemic events, veri-
fied by computed tomography (CT) and/or the course
of neurologic disorders. Peripheral arterial occlusive dis-
ease (PAOD) was recorded if patients had at a minimum
strength-dependent pain leading to a maximum walking
distance of below 200 m (corresponding to Fontaine’s
stage IIb of PAOD), ischemic rest pain (Fontaine’s stage
III), or ulcers of the lower extremity due to macrovascu-
lar disease (stage IV). Diabetes was classified according
to the recommendations of the committee on the diagno-
sis and classification of diabetes mellitus in 1997 [21]. The
definition of diabetes in this study, however, included a
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requirement for a minimum of 2 years’ duration of the
disease.
Parameters of nutritional status
The body mass index (BMI) (kg/m2) as well as the
serum levels of albumin, cobalamin, and folic acid were
used as markers of nutritional status.
Follow-up
Follow-up ended with the occurrence of cardiovas-
cular events, initiation of dialysis treatment (excepting
hemodialysis), renal transplantation (only hemodialysis
group), a change of treatment location, or death. The
presence of cardiovascular events was defined if any event
of acute myocardial infarction, angina pectoris, or cere-
brovascular disease, according to the criteria mentioned
above, occurred. All participants had at least one ECG
measurement per year. The end point of PAOD was di-
agnosed as described above or if a preexisting stage of
PAOD had to be upgraded. Two cases of death following
fatal cardiac failure in the hemodialysis group were clas-
sified as acute myocardial infarction because the autopsy
revealed the total occlusion of at least one of the main
coronary arteries.
Laboratory analysis
Blood samples were drawn after an overnight fast-
ing; the serum samples were immediately centrifuged
(3000 rpm, 4◦C) and cooled within 1 hour and stored at
−80◦C until analysis was performed. Total pentosidine
(free and protein-bound) was measured using the high-
performance liquid chromatography (HPLC) assay de-
scribed by Miyata et al [10]. The modifications used in
our lab have been described elsewhere [20]. The intra-
and interassay coefficients of variation (CV) were <3%
and <6%, respectively. CML serum concentrations were
determined with an intra- and interassay CV of <5% and
<7% by a competitive enzyme-linked immunosorbent as-
say (ELISA) using streptavidine-coated microtiter plates
(Roche Diagnostics GmbH, Penzberg, Germany). Imida-
zolone was measured as described for the CML-ELISA,
except for changes as previously described [20], with
an intra- and interassay CV of <4% and <8%, re-
spectively. The imidazolone antibody was prepared and
characterized as already published [6]. Imidazolone con-
centrations were expressed as arbitrary units of imida-
zolone (AU/L). Serum tHcy (free and protein-bound)
and its metabolites cystathionine, methylmalonic acid
(MMA) and 2-methylcitric acid (2-MCA) were measured
by gas chromatographic-mass spectrometric (GC-MS)
assay using stable isotope dilution as already de-
scribed [22]. The intra-assay and interassay CV for tHcy
are 3.9% and 4.5%, for cystathionine 1.8%/7%, for
MMA 1.3%/9.1%, and for total 2-MCA (2-MCAtotal)
2.6%/10%, respectively. Serum cobalamin and folate
were determined by luminescence assay (Bayer Co.,
Chiron, Leverkusen, Germany) using a purified intrinsic
factor and a purified folate binding protein. CRP was
determined using a turbidimetric immunoassay (Wako
Chemicals, Neuss, Germany) with a detection limit of
2 mg/L. Parameters such as lipid levels, creatinine, and
albumin were determined using automated standardized
laboratory techniques.
Statistical methods
The results are given as means with standard devia-
tions (mean ± SD) and medians. The Mann-Whitney U
test was used to compare differences between two inde-
pendent groups, the Spearman rank correlation test for
estimating relationships between variables. A P value <
0.05 was considered as statistically significant, with the ex-
ception of the relationships between variables (P value <
0.001). The associations between the potential risk factors
and cardiovascular events in the total group are described
by hazard ratios [denoted as relative risk (RR)] and the
corresponding 95% CI. Patients were separated into two
groups above and below the cutoff levels (medians in the
total group) of the risk factors. Smokers, diabetes mellitus
patients and patients with a past history of cardiovascular
events were compared to those without these risk factors.
Hemodialysis and renal transplant recipients were com-
pared to CRF patients used as a reference category. The
categorization of the continuous variables was necessary
due to a nonlinear log hazard in the covariates of interest
[23]. Relative risk for cardiovascular events was calcu-
lated by univariate following stepwise multivariate Cox
regression analysis. Due to the limited number of patients,
only variables on a significance level of P ≤ 0.20 in the
univariate analysis were entered in the initial multivari-
ate model. Covariates with P < 0.10 were included in the
final multivariate model. In addition, chi-squared statis-
tics were used. Statistics were done using the software
Statistical Package of Social Science (SPSS 10.0, 2000)
(SPSS Inc., Chicago, IL, USA).
RESULTS
Biochemical and clinical characteristics of subgroups
at baseline (selected parameters)
Table 1 shows the characteristics of all groups. BMI,
diastolic blood pressure, CRP (P < 0.001, respectively),
and high-density lipoprotein (HDL) cholesterol (P =
0.003) were significantly lower in hemodialysis com-
pared with CRF and creatinine levels were significantly
higher (P < 0.001, respectively) (Table 1). Albumin,
HDL cholesterol levels, and diastolic blood pressure in
hemodialysis patients were significantly lower as com-
pared with renal transplant recipients (P ≤ 0.001, respec-
tively); age, CRP, and creatinine were each increased
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Table 1. Characteristics of 99 patients with chronic renal failure (CRF), 84 hemodialysis patients and 49 patients after renal transplantation
Total CRF Hemodialysis Renal transplant recipients Normal rangea
Gender male/female 150/82 65/34 50/34 35/14
Diabetes/smokers 70/42 32/22 31/9 7/11
History of cardiovascular events 79 20 42 17
Age years
Mean ± SD 57.6 ± 13.1 58.3 ± 12.9b 61.1 ± 12.5b 50.2 ± 11.8c
Median 58.6 59.2 61.5 54.0
(min–max) (24–87) (33–83) (24–87) (25–71)
Body mass index kg/m2
Mean ± SD 26 ± 4 28 ± 5b,d 25 ± 4e 25 ± 3e 20–25
Median 26 27 25 25
(min–max) (15–47) (19–47) (15–39) (18–35)
Creatinine lmol/L
Mean ± SD 482 ± 318 381 ± 213b,d 794 ± 220b,e 150 ± 66c 80–95
Median 453 324 745 142
(min–max) (64–1481) (119–1107) (397–1481) (64–371)
C-reactive protein mg/L
Mean ± SD 17.2 ± 28.2 23.5 ± 35.9b,d 16.2 ± 22.1b,e 6.3 ± 12.1c <5.0
Median 6.7 9.2 5.0 3.2
(min–max) (1.0–236.9) (4.1–236.9) (1.0–96.0) (1.0–84.5)
Albumin g/L
Mean ± SD 39.2 ± 5.3 38.7 ± 5.1b 38.0 ± 5.0b 42.5 ± 5.0c 35–55
Median 39.7 39.6 38.3 42.6
(min–max) (20.1–65.1) (20.1–55) (25.3–54.2) (31.5–65.1)
Low-density lipoprotein mmol/L
Mean ± SD 3.5 ± 1.2 3.7 ± 1.2 3.4 ± 1.1 3.3 ± 1.2 <3.5
Median 3.5 3.6 3.4 3.2
(min–max) (0.88–8.11) (0.9–8.1) (0.9–7.6) (0.9–5.2)d
High-density lipoprotein mmol/L
Mean ± SD 1.3 ± 0.8 1.2 ± 0.4b,d 1.1 ± 0.4b,e 1.7 ± 1.6c >1.1
Median 1.2 1.2 1.0 1.4
(min–max) (0.36–10.8) (0.5–2.7) (0.4–2.3) (0.5–10.8)
Triglycerides mmol/L
Mean ± SD 2.2 ± 1.5 2.2 ± 1.3 2.1 ± 1.3 2.6 ± 2.0 <2.29
Median 1.9 2.0 1.7 1.9
(min–max) (0.34–11.1) (0.3–8.2) (0.4–6.7) (0.5–11.1)
Systolic blood pressure mm Hg
Mean ± SD 139 ± 20 140 ± 19 140 ± 22 137 ± 17 <140
Median 140 140 143 134
(min–max) (88–192) (100–192) (88–186) (90–176)
Diastolic blood pressure mm Hg
Mean ± SD 81 ± 11 83 ± 11d 77 ± 11b,e 83 ± 11d <90
Median 80 85 77 84
(min–max) (38–109) (51–105) (38–100) (49–109)
Cobalamin pmol/L
Mean ± SD 341 ± 170 352 ± 201 347 ± 146b 310 ± 140d 222–814
Median 311 314 312 266
(min–max) (110–1476) (110–1476) (139–1040) (151–811)
Folate nmol/L
Mean ± SD 25.5 ± 23.2 19.6 ± 9.8d 37.0 ± 34.4b,e 19.2 ± 9.7d 6.8–38.6
Median 19.2 16.9 27.4 16.8
(min–max) (4.7–178) (4.7–52.0) (8.4–178.0) (7.5–52.0)
aNormal ranges referred to healthy, middle-aged men and women without cardiovascular risk profile.
bP ≤ 0.001 compared to renal transplant recipient, P = 0.039 for cobalamin.
cP < 0.001 compared to chronic renal failure and hemodialysis, P ≤ 0.023 for high-density lipoprotein cholesterol.
dP ≤ 0.001 compared to hemodialysis, P = 0.003 for high-density lipoprotein cholesterol.
eP ≤ 0.001 compared to chronic renal failure, P = 0.003 for high-density lipoprotein cholesterol.
(P < 0.001, respectively). In addition, renal transplant
recipients revealed significantly higher albumin levels
(P < 0.001) and HDL cholesterol levels (P = 0.023) as
compared with CRF and hemodialysis patients; age, cre-
atinine, and CRP were significantly lower (P < 0.001, re-
spectively). BMI in renal transplant recipients was lower
as compared with CRF (P = 0.001, respectively).
AGEs, tHcy, related metabolites, folate, and vitamin B12
At baseline, the mean serum levels of the AGEs were
found to be significantly increased above the reference
interval (healthy subjects) in all three groups (P < 0.001)
(Fig. 1). The hemodialysis group showed the highest
levels for all AGEs (P < 0.001 vs. CRF and renal
transplant recipients). Compared to CRF, CML in renal
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Fig. 1. Serum levels of advanced glycation end products (AGEs), total homocysteine (tHcy), and metabolites at baseline of 99 patients with
chronic renal failure (CRF), 84 hemodialysis patients (HD), and 49 patients after renal transplantation (RTR), mean, SD, median (—), respectively.
Abbreviations are: CML, Ne-carboxymethyllysine; CYSTA, cystathionine; MMA, methylmalonic acid; 2-MCAtotal, total 2-methylcitric acid.
transplant recipients was significantly increased and im-
idazolone significantly decreased (P < 0.001). Mean
serum levels of tHcy and of the metabolites were sig-
nificantly increased, compared to controls (P < 0.001 for
tHcy, P < 0.01 for cystathionine, MMA, and 2-MCA).
Hyperhomocysteinemia >15 lmol/L was present in 82%
(N = 81) of the CRF patients, 89% (N = 75) of the
hemodialysis patients and 63% (N = 31) of the renal
transplant recipients. Hemodialysis patients had signifi-
cantly higher levels of cystathionine, MMA, 2-MCA, and
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Table 2. Significant relationships between selected parameters according to Spearman-Rho test (total group, N = 232), R values are given,
P < 0.001, respectively
Albumin CML Imidazolone Pentosidine tHcy Cystathionine MMA 2-MCA
Age −0.27 NS 0.35 0.34 NS 0.25 0.34 0.33
Albumin — NS −0.31 NS NS NS NS NS
Body mass index −0.38 NS −0.30 NS NS NS NS
C-reactive protein −0.30 NS NS NS NS NS NS NS
Cobalamin NS NS NS NS NS NS NS NS
Folic acid NS 0.29 0.30 0.27 −0.30 NS NS 0.27
Creatinine NS 0.60 0.69 0.73 0.32 0.53 0.55 0.79
CML NS —
Imidazolone −0.31 0.57 —
Pentosidine NS 0.82 0.65 —
tHcy NS NS NS 0.27 —
Cystathionine NS 0.47 0.49 0.56 0.40 —
MMA NS 0.61 0.57 0.68 0.37 0.60 —
2-MCA NS 0.63 0.69 0.75 0.36 0.63 0.66 —
Abbreviations are: CML, Ne-carboxymethyllysine; tHcy, total homocysteine; MMA, methylmalonic acid; 2-MCAtotal, total 2 methylcitric acid.
folic acid as compared to CRF and renal transplant re-
cipients (P = 0.001, respectively). tHcy and cobalamin
in hemodialysis patients were significantly increased as
compared with renal transplant recipients (P = 0.024
and P = 0.039, respectively), whereas CRF revealed
significantly higher levels of cystathionine (P = 0.01),
MMA, and 2-MCA (P = 0.001, respectively) in compar-
ison to renal transplant recipients (Table 1) (Fig. 1).
Relationships within selected variables
Significant parameter correlations in the total group
are shown in Table 2. No significant relationships be-
tween tHcy and CRP, BMI or albumin levels could
be found in the total group, whereas in hemodialysis
patients, tHcy was positively correlated with albumin
(R = 0.369, P = 0.001). Expecting a negative correla-
tion of imidazolone with albumin (Table 2), no signifi-
cant correlation between albumin and the AGEs could be
found in the total group. In hemodialysis patients, beside
pentosidin (R = 0.29), CML was correlated with tHcy
(R = 0.37, P < 0.001, respectively). No significant correla-
tion of AGEs with HDL, low-density lipoprotein (LDL)
and triglycerides could be found in the total group or in
any of the subgroups.
Parameters in hemodialysis patients with low-flux
vs. high-flux membrane dialysis
With the exception of fibrinogen (median 3.8 in high
flux vs. 4.4 in low-flux, P = 0.010) and creatinine levels
(823 lmol/L vs. 724 lmol/L, P = 0.009), none of the pa-
rameters showed any difference between high- and low-
flux membrane dialyzed patients.
Parameters in patients with vs. without history of
cardiovascular events
In CRF patients, no significant differences between pa-
tients with a history of cardiovascular events compared to
those without were found for all baseline data, including
markers of nutrition and the levels of AGEs, tHcy, and
metabolites, with the exception of pentosidine (median
435 pmol/mL in cardiovascular events vs. 265 pmol/mL
in noncardiovascular events, P = 0.032) and MMA
(655 nmol/L vs. 473 nmol/L, P = 0.044). In hemodial-
ysis patients, albumin (median 37.5 g/L in cardiovascu-
lar events vs. 38.9 g/L in noncardiovascular events, P =
0.014), tHcy (20.1 lmol/L vs. 22.9 lmol/L, P = 0.013),
imidazolone (2.7 AU/L vs. 2.2 AU/L, P = 0.015) as well
as CRP (11.0 mg/L vs. 4.9 mg/L, P = 0.001) were found
to be significantly different. The renal transplant recipi-
ent group revealed significant differences for age (median
57.0 years in cardiovascular events vs. 48.5 years in non-
cardiovascular events, P = 0.021) and HDL cholesterol
(1.53 mmol/L vs. 1.30 mmol/L, P = 0.016).
Follow-up/dropouts of the total group
Median follow-up time was 26 (1 to 62) months. A total
of 56 patients (20 female and 36 male, mean age 59.4 ±
11.8 years) dropped out of the study because of renal
transplantation (N = 7) or change of dialysis center (N =
2) in the hemodialysis group or due to dialysis initiation
in the CRF (N = 42) and renal transplant recipient group
(N = 5). Baseline characteristics were the following: CRP
(median 7.4 mg/L in dropouts vs. 6.1 mg/L in remaining
subjects, P = 0.039), urea (24.8 mmol/L vs. 19.8 mmol/L,
P < 0.001), tHcy (24.5 lmol/L vs. 20.0 lmol/L, P = 0.001),
diastolic blood pressure (87 mm Hg vs. 80 mm Hg, P =
0.016), LDL cholesterol (3.8 mmol/L vs. 3.2 mmol/L, P =
0.002), and percentage of prior cardiovascular events
(22.8% vs. 37.7%, P = 0.034).
Total and cardiovascular mortality
A total of 40 patients died during the follow-up period.
Twenty-four patients died from acute myocardial infarc-
tion; 19 in the hemodialysis group, four in the CRF group,
and one in the renal transplant receipt group. Two cases
of death in hemodialysis patients following fatal cardiac
failure were classified as acute myocardial infarction, be-
cause the autopsy revealed the total occlusion of at least
one of the main coronary arteries. Seven patients died
of cerebrovascular complications; two patients in CRF
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and five in the hemodialysis group. Nine patients died of
other causes, two outside of the hospital without a known
cause.
Cardiovascular events during follow-up
Fifty-three cases of cardiovascular events, including
cardiovascular death, occurred during the follow-up (to-
tal group). Thirty (18 acute myocardial infarction, one
angina pectoris, five cerebrovascular events, and six
PAOD) of the 53 cardiovascular events occurred in sub-
jects with a history of prior cardiovascular events vs. 23
in subjects without (P < 0.001). Fourteen of the sub-
jects with recurrent cardiovascular events were type 2
diabetics and two were type 1 diabetics, five were smok-
ers. In nine cases, the cardiovascular event was of the
same type (five acute myocardial infarction, one angina
pectoris, and three PAOD). Twenty-one deaths due to
cardiovascular causes (16 due to acute myocardial infarc-
tion and five due to cerebrovascular disease) occurred in
patients having a history of cardiovascular events, 11 of
them had type 2 diabetes, one case with type 1 diabetes,
and three were smokers. Among the 99 CRF patients, 11
had cardiovascular events (acute myocardial infarction,
four; angina pectoris, one; cerebrovascular disease, five;
peripheral vascular disease, one). In the 84 hemodialysis
patients, 39 suffered from cardiovascular events, includ-
ing acute myocardial infarction in 21 cases, angina pec-
toris in six, cerebrovascular disease in four as well as pe-
ripheral vascular disease in eight patients. In the 49 renal
transplant recipients, one patient in each case revealed
acute myocardial infarction, angina pectoris as well as
cerebrovascular disease.
Diabetics and nondiabetics
In CRF, differences between diabetic and nondiabetic
patients existed (median values in diabetic vs. nondia-
betic, respectively) for cystathionine (1597 nmol/L vs.
812 nmol/L, P = 0.006), diastolic blood pressure
(74 mm Hg vs. 90 mm Hg, P < 0.001), HDL cholesterol
(1.0 mmol/L vs. 1.2 mmol/L, P = 0.005), LDL choles-
terol (3.2 mmol/L vs. 3.7 mmol/L, P = 0.024), and imida-
zolone concentrations (1.6 AU/L vs. 1.2 AU/L, P = 0.007).
Hemodialysis patients with diabetes had lower levels of
tHcy (21.4 lmol/L vs. 22.9 lmol/L, P = 0.007), 2-MCA
(1269 nmol/L vs. 1434 nmol/L, P = 0.002), creatinine
(733 lmol/L vs. 804 lmol/L, P = 0.019), CML (1517 ng/
mL vs. 1668 ng/mL, P = 0.036), and pentosidine
(1170 pmol/mL vs. 1503 pmol/mL, P = 0.027) but higher
triglyceride levels (2.3 mmol/L vs. 1.5 mmol/L, P = 0.015)
compared with nondiabetics. In renal transplant recipi-
ents, none of the parameters showed any difference be-
tween diabetic and nondiabetic patients.
Aspirin, CRP, and cardiovascular events
No significant differences in CRP levels between pa-
tients treated with aspirin medication and those with-
Table 3. Adjusted relative risk estimates for cardiovascular events
(N = 53) during a median follow-up of 26 months in 232 patients with
chronic kidney diseases resulting from final multivariate Cox
proportional hazards model
Relative risk (RR) estimate
(95% CI) adjusted final
Categories of risk factorsa model (P < 0.10) P value
End-stage renal diseaseb 4.88 (2.40–9.89) <0.001
Diabetes mellitus 2.06 (1.17–3.60) 0.013
C-reactive protein 2.00 (1.11–3.60) 0.021
>median (6.7 mg/L)
aDefining relative risk compared to complementary categories.
bHemodialysis treatment; defining relative risk compared to chronic renal fail-
ure (reference).
out could be found in any group, whereas patients with
cardiovascular events during follow-up had significantly
higher CRP levels compared to patients without (median
10.7 mg/L vs. 6.4 mg/L, P = 0.003). Thirty-five percent of
patients with aspirin treatment had new cardiovascular
events during follow-up compared to 19% without (P =
0.013).
Relationships between the variables of interest and
vascular diseases during follow-up (total group)
In univariate analysis, higher values for age, CRP,
CML, pentosidine, imidazolone, cystathionine, MMA,
and 2-MCA at baseline (categorial variables, separated
by the median values in the total group, respectively)
(Table 1) (Fig. 1) and lower values of albumin, BMI,
folic acid, HDL cholesterol as well as the existence of
diabetes mellitus, smoking, a history of cardiovascular
events, male gender, and advanced stage of renal in-
sufficiency (hemodialysis and renal transplant recipients
vs. CRF, respectively) were associated with the subse-
quent development of cardiovascular events (P < 0.2).
Final multivariate Cox regression analysis showed dia-
betes mellitus (RR 2.06, 95% CI 1.17–3.60, P = 0.013),
hemodialysis treatment (RR 4.88, 95% CI 2.40–9.89,
P < 0.001) as well as elevated CRP levels (RR 2.00, 95%
CI 1.11–3.60, P = 0.021) as correlated to increased risk
for cardiovascular events (Table 3). Neither elevated lev-
els (>median, respectively) of CML (>832 ng/mL), im-
idazolone (>1.50 AU/L) nor of tHcy (>21.2 lmol/L)
and its metabolites cystathionine (>1261 nmol/L), MMA
(>602 nmol/L), and 2-MCA (>876 nmol/L) were signif-
icantly associated with an increased risk for cardiovas-
cular events during follow-up. Higher pentosidine levels
(>491 pmol/mL) tended to almost reach significance in
the final backward model (P = 0.06).
DISCUSSION
In patients with chronic renal failure, risk of cardiovas-
cular morbidity and mortality is substantially increased
[1]. In addition to the well-known cardiovascular risk fac-
tors such as diabetes mellitus or ESRD, parameters such
as elevated serum levels of CRP, fibrinogen, and tHcy
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have been newly defined as cardiovascular risk factors
[12–14, 16, 17, 24, 25]. Evidence increasingly suggests that
AGEs are also potential candidates enhancing vascular
complications [7, 26]. The present study tested the hy-
pothesis that related to renal impairment, patients with
chronic kidney disease, including CRF, maintenance dial-
ysis patients as well as renal transplant recipients, are
at increased risk for cardiovascular events due to the
elevation of tHcy, their related metabolites cystathion-
ine, MMA, and 2-MCA as well as of the AGEs CML,
pentosidine, and imidazolone. The influence of chronic
inflammation as well as malnutritional status mainly ex-
pressed by increased levels of CRP and fibrinogen and
decreased serum albumin levels [3, 4, 12, 13, 24] was also
tested.
As stated by Suliman et al [15], the causative role of
hyperhomocysteinemia for atherothrombotic diseases in
consideration of nutritional status remains unclear. In
our study, 82% of CRF, 89% of hemodialysis patients,
and 63% of renal transplant recipients had tHcy levels
>15 lmol/L. Comparable to Suliman et al, hemodialysis
patients with a history of cardiovascular events revealed
lower tHcy (P = 0.013) and albumin levels (P = 0.014)
compared to those without. Hemodialysis patients had
the lowest mean albumin concentration (38.0 ± 5.0 g/L)
of all groups. Only in hemodialysis patients, albumin cor-
related with tHcy (R = 0.37, P = 0.001) suggesting that
malnutrition along with lower tHcy levels mainly occurs
in dialyzed patients. Interestingly, in contrast to the total
group, in hemodialysis patients no correlation between
albumin and CRP existed, indicating that malnutrition
in hemodialysis patients is not urgently related to acute
phase response, respectively, caused by it, as stated by
Stenvinkel et al [4] in a predialysis population study. A
possible role of the metabolites cystathionine, MMA, and
2-MCA in addition to increased tHcy levels has not yet
been fully clarified, although their extraordinary increase
in CRF, above all in hemodialysis patients [27], as con-
firmed by our results (Fig. 1) is caused both by a reduced
glomerular filtration rate as well as by functional defi-
ciencies of the vitamin B6, vitamin B12, and folic acid [27,
28]. The inhibition of metabolic steps due to uremia may
play a further role [28]. Metabolites and tHcy are pos-
sibly more closely linked to renal function rather than
nutritional status, which might suggest a cardiovascular
risk potential due to vitamin deficiency and disturbed Hcy
metabolism leading to a generalized increase in thiol ox-
idation in renal failure [3, 18, 28]. The increased levels
of the metabolites, additional to elevated tHcy in renal
transplant recipients, showing a mean creatinine of only
150 lmol/L, might be an indicator for this as well.
The results of the present study regarding the concen-
tration of AGEs in chronic kidney disease confirm pre-
vious findings [10, 11]. In a preliminary study recently
published [20], CRF, hemodialysis, and renal transplant
recipient patients with left ventricular hypertrophy re-
vealed higher AGE levels. Only minimal data exist cor-
relating tHcy and AGE levels in testing the hypothesis
of synergistic action of both in the generation of vascular
damage [22] as suggested in diabetic patients [29]. In the
data presented here, pentosidine showed a constant cor-
relation with tHcy in the total group (Table 2) as well as
in hemodialysis patients. In hemodialysis patients, CML
correlated additionally with tHcy, whereas imidazolone
showed no correlation with tHcy in the total group or
in any of the subgroups. Beyond their close association
with renal function (Table 2), these results might suggest
a link between oxidatively formed AGEs and tHcy levels
confirming both as markers of increasing oxidative stress
in CRF and hemodialysis as indicated by Himmelfarb et
al [3]. Moreover, it might confirm that “carbonyl stress”
results from oxidative stress [28]. The formation of gly-
coxidation products, such as CML and pentosidine, is de-
pendent on the concentration of carbohydrate precursors
and of reactive oxygen, the autooxidation of homocys-
teine to homocystine may result in such reactive oxygen
species [18]. In the same manner, one would expect that
the non-oxidatively formed imidazolone would show no
relationship with tHcy; exactly this could be shown for all
groups. However, no relationship of AGEs with CRP in
the total group or in any subgroup could be determined
indicating that “carbonyl stress” is not as closely related
to chronic inflammation than the loss of renal function
itself, leading to a decreased renal detoxification or clear-
ance of reactive carbonyl compounds which act as AGE
precursors [26]. The strong correlation of the AGEs with
the creatinine level as shown for the total group (Table 2)
emphasizes this. In a prospective study investigating di-
alyzed patients, Schwedler et al [11] showed that higher
serum levels of AGEs were linked to a better survival
and were associated with higher levels for creatinine, al-
bumin and blood urea nitrogen, which was interpreted as
an indicator of a better nutritional status; survival wors-
ened when low AGEs and high CRP levels coincided.
In contrast, in the hemodialysis group of our study, no
significant correlation between AGEs and albumin and
creatinine could be found, suggesting AGEs are not con-
stantly linked to albumin and creatinine levels, especially
under conditions of chronic hemodialysis treatment. In
animal models, the increase in CML tissue levels was at-
tributed mainly to hyperlipidemia [31], and AGEs cor-
related with serum triglycerides in nonuremic patients
with diabetes mellitus [32]. In our study, no significant
correlation between serum lipid levels and AGEs, espe-
cially CML, could be found, possibly indicating a differ-
ent impact of lipids for the AGE formation in CRF and,
furthermore, that AGE serum levels in CRF might not
correspond to tissue levels.
Our main findings were that elevated CRP levels, dia-
betes, and hemodialysis treatment were associated with
increased morbidity for cardiovascular events (Table 3),
whereas elevated serum levels of AGEs, tHcy, or any of
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the metabolites were not related to elevated cardiovas-
cular event risk. Only for increased pentosidine could
be detected a trend toward a possible association with
an increased risk. These results confirm numerous pre-
vious findings in which diabetes, elevated CRP levels,
and hemodialysis treatment could be demonstrated as
independent risk factors for cardiovascular events, espe-
cially in chronic renal disease patients [1, 2, 13, 24, 33].
Nevertheless, it should be noted that there are some lim-
itations to our study: for statistical reasons stated above,
it was necessary to use the categorization of continuous
variables. Moreover, due to the limited number of pa-
tients recruited in this single-center study, we performed
median dichotomization rather than comparing quartiles
leading to the possibility that only tHcy or AGE levels
in the upper 20th to 25th percentile distribution could
have been associated with a higher risk for cardiovascu-
lar events as shown for tHcy by others [16, 17]. Another
problem might be that AGEs, tHcy, and the metabolites
were measured only at baseline levels and might have
been influenced by short-term changes in formation and
metabolism. Furthermore, it has to be taken into account,
that the hemodialysis group, which was found to have the
highest tHcy concentrations within the study population,
was treated with vitamin supplementation, possibly cov-
ering up any relationship between tHcy and cardiovas-
cular events, if not preventing it. However, since ESRD
did lead to a risk potentiation for cardiovascular events
in our study population (Table 3) and maximum serum
levels of tHcy, metabolites, and AGEs were observed in
this group (Fig. 1), one can speculate that the interaction
between these enhanced parameters in ESRD might play
a role as well.
Himmelfarb et al [3] hypothesize oxidant stress en-
hanced by chronic inflammation and malnutrition as a
unifying concept of cardiovascular disease in uremia. Our
data are not contradictory to this concept, but in a con-
firmation of previous findings [11–13, 24], our results in-
dicate a more pronounced role for inflammation itself, as
expressed in increased CRP levels. Although serum levels
of CRP are independent of the glomerular filtration rate,
it is known that even in predialysis patients CRP levels
begin to rise, potentially related to a sustained inflamma-
tory response in CRF [4]. Since standard assays for CRP
lack the sensitivity to determine levels of inflammation
within the normal range of the general population, ap-
plication of highly sensitive CRP (HSCRP) testing has
become a tool in cardiovascular risk estimation [34]. For
each quintile increase in HSCRP (0.1 to 0.69 mg/L; 0.7
to 1.1 mg/L; 1.2 to 1.9 mg/L; 2.0 to 3.8 mg/mL; and
>3.8 mg/L), the adjusted risk of suffering a future cardio-
vascular event increased 26% for healthy American men
(95% CI 11% to 44%, P < 0.005) and 33% for women
(95% CI 13% to 56%, P < 0.001) [34]. In patients with
CRF, especially in ESRD, elevated CRP levels, which are
present in up to 65% of those patients, were also linked
to increased all-cause and cardiovascular mortality [4, 12,
13, 24]. Zimmerman et al [13] found a significant increase
of all-cause and cardiovascular mortality due to increased
CRP in a cohort of 280 hemodialysis patients (4.6-fold
and 5.5-fold higher in the highest quartile (>15.8 mg/L)
compared to the lowest (<3.3 mg/L), respectively. Agree-
ing with our results, Pecoits-Filho et al [35] showed a
median CRP level of 6.3 mg/L in a predialysis cohort.
In other studies, mean CRP levels of 18 mg/L (predialy-
sis) and 16.3 mg/L/16.2 mg/L (hemodialysis) were shown
[4, 13, 33] comparable to the mean CRP levels of our
study. All results from these studies, including ours, show
that CRP levels were clearly increased above the nor-
mal range of the general population [34] suggesting that
a standard assay for CRP testing might be sufficient
for the estimation of increased cardiovascular risk due
to elevated CRP in CRF and ESRD. Evidence increas-
ingly points to the potential of reducing CRP levels by
the administration of high dosages of aspirin (at least
160 mg/day) [36, 37] and by lipid-lowering drugs such
as the 3-hyxdroxy-3-methylglutaryl coenzyme A(HMG-
CoA) reductase inhibitors [38, 39] for both primary and
secondary prevention of cardiovascular disease in pa-
tients without renal failure. Concerning therapy with
aspirin, comparable to Schwedler et al [11], our study
showed no benefits derived from aspirin treatment re-
garding CRP levels and rate of cardiovascular events. In
the literature, as far as we know, no data exist as yet which
have demonstrated a drug-mediated CRP reduction in
patients with CRF. Our findings might be related to the
use of a maximum dose of only 100 mg/day; comparable
doses had no effect on CRP levels even in healthy volun-
teers [40]. Other possible confounders are, for example,
the previous cardiovascular event rate (mainly patients
with previous cardiovascular events used aspirin), and
that most subjects in the hemodialysis group, showing the
highest rate of cardiovascular events, were aspirin users.
Prospective placebo-controlled trials would help deter-
mine the benefits of aspirin and lipid-lowering drugs in
reducing the risk of future cardiovascular events in CRF
and ESRD by decreasing CRP concentrations.
Our data underline that the presence of diabetes re-
mains a cardiovascular risk factor of extraordinary impor-
tance, especially in chronic kidney disease. The presence
of both chronic kidney disease and diabetes leads to the
abysmal prognosis of diabetes patients when requiring
dialysis treatment, as reported for type 2 diabetes [33],
and is further intensified by increasing CRP levels [4, 11–
13, 24].
CONCLUSION
Our data provide evidence that risk factors such as el-
evated CRP levels, the presence of diabetes, and the ex-
tent of ESRD seem to play a more important role for the
cardiovascular outcome of patients with chronic kidney
diseases than the laboratory findings of elevated serum
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levels of tHcy, cystathionine, MMA, 2-MCA, or of the
AGEs CML, pentosidine, and imidazolone. As evidence
clearly shows that elevated CRP correlates with nega-
tive cardiovascular outcome as confirmed by this study,
CRP testing can be recommended for determination of
increased cardiovascular risk in patients with chronic
renal insufficiency; a standard CRP assay would be
sufficient.
Reprint requests to Dr. med. Martin Busch, Friedrich-Schiller-
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